Results 171 to 180 of about 262,476 (307)
The Study Groups of the Portuguese Society of Endocrinology, Diabetes and Metabolism
openaire +1 more source
ABSTRACT Objective This study aimed to quantify the impact of adolescents' exposure to unhealthy food marketing in real‐world digital environments. Methods We conducted a single‐blinded randomized field experiment including 121 Australian adolescents aged 16–17.
Max Treu +4 more
wiley +1 more source
Diabetes Fact Sheet 2025: Comparative Epidemiology and Clinical Features of Obese and Non-Obese Diabetes in Korea. [PDF]
Kim JH +7 more
europepmc +1 more source
This study identifies G protein‐coupled receptor 17 (Gpr17) as a novel regulator of leptin and insulin sensitivity. Using complementary knockout models, we demonstrate that Gpr17 deletion enhances energy expenditure, restores leptin responsiveness, and improves insulin sensitivity, revealing Gpr17 as a potential therapeutic GPCR target for obesity and ...
Xun Sun +8 more
wiley +1 more source
Response to “Stopping Spin at the Source: Learning From an Example in Obesity”
Obesity, EarlyView.
Huasheng Xiang +5 more
wiley +1 more source
ABSTRACT Objective This study aimed to describe parental communication with children around obesity management medications (OMMs) and child, parent, and family factors associated with communication. Methods Parents (N = 211; 80% mothers; 89% White) prescribed OMMs at a medical center participated in a survey about communication with children about OMM ...
Keeley J. Pratt +3 more
wiley +1 more source
Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial. [PDF]
Bergenstal RM +15 more
europepmc +1 more source
Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications
ABSTRACT Objective This study compared changes in health care costs and use across cohorts initiating four obesity medications (OMs). Methods Commercial insurance claims were used to identify new initiators of phentermine (n = 136,788), phentermine‐topiramate‐ER (n = 13,888), naltrexone‐bupropion‐SR (n = 28,712), or liraglutide (n = 49,266) for obesity.
Kristina H. Lewis +10 more
wiley +1 more source
Navigating the AI Revolution: A New Chapter for the Diabetes and Metabolism Journal. [PDF]
Noh J.
europepmc +1 more source

